Literature DB >> 20640572

Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion.

Alexander J Muller1, James B DuHadaway, Mee Young Chang, Arivudinambi Ramalingam, Erika Sutanto-Ward, Janette Boulden, Alejandro P Soler, Laura Mandik-Nayak, Susan K Gilmour, George C Prendergast.   

Abstract

Indoleamine 2,3-dioxygenase (IDO) is generally considered to be immunosuppressive but recent findings suggest this characterization oversimplifies its role in disease pathogenesis. Recently, we showed that IDO is essential for tumor outgrowth in the classical two-stage model of inflammatory skin carcinogenesis. Here, we report that IDO loss did not exacerbate classical inflammatory responses. Rather, IDO induction could be elicited by environmental signals and tumor promoters as an integral component of the inflammatory tissue microenvironment even in the absence of cancer. IDO loss had limited impact on tumor outgrowth in carcinogenesis models that lacked an explicit inflammatory tumor promoter. In the context of inflammatory carcinogenesis where IDO was critical to tumor development, the most important source of IDO was radiation-resistant non-hematopoietic cells, consistent with evidence that loss of the IDO regulatory tumor suppressor gene Bin1 in transformed skin cells facilitates IDO-mediated immune escape by a cell autonomous mechanism. Taken together, our results identify IDO as an integral component of 'cancer-associated' inflammation that tilts the immune system toward tumor support. More generally, they promote the concept that mediators of immune escape and cancer-associated inflammation may be genetically synonymous.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20640572      PMCID: PMC2999622          DOI: 10.1007/s00262-010-0891-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  47 in total

1.  Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate.

Authors:  Alexander J Muller; James B DuHadaway; Daniel Jaller; Peter Curtis; Richard Metz; George C Prendergast
Journal:  Cancer Res       Date:  2010-02-16       Impact factor: 12.701

Review 2.  Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.

Authors:  Thomas F Gajewski
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

3.  Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.

Authors:  Alexander J Muller; Madhav D Sharma; Phillip R Chandler; James B Duhadaway; Mary E Everhart; Burles A Johnson; David J Kahler; Jeanene Pihkala; Alejandro Peralta Soler; David H Munn; George C Prendergast; Andrew L Mellor
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-24       Impact factor: 11.205

4.  Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity.

Authors:  Million Arefayene; Santosh Philips; Donghua Cao; Sudharani Mamidipalli; Zeruesenay Desta; David A Flockhart; David S Wilkes; Todd C Skaar
Journal:  Pharmacogenet Genomics       Date:  2009-06       Impact factor: 2.089

5.  High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome.

Authors:  Martine E D Chamuleau; Arjan A van de Loosdrecht; Corine J Hess; Jeroen J W M Janssen; Adri Zevenbergen; Ruud Delwel; Peter J M Valk; Bob Löwenberg; Gert J Ossenkoppele
Journal:  Haematologica       Date:  2008-12       Impact factor: 9.941

6.  Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.

Authors:  Ke Pan; Hui Wang; Min-shan Chen; Hua-kun Zhang; De-sheng Weng; Jun Zhou; Wei Huang; Jian-jun Li; Hai-feng Song; Jian-chuan Xia
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-26       Impact factor: 4.553

7.  Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target.

Authors:  Agnieszka K Witkiewicz; Christina L Costantino; Richard Metz; Alexander J Muller; George C Prendergast; Charles J Yeo; Jonathan R Brody
Journal:  J Am Coll Surg       Date:  2009-05       Impact factor: 6.113

8.  Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer.

Authors:  Mee Young Chang; Janette Boulden; Jessica B Katz; Liwei Wang; Thomas J Meyer; Alejandro Peralta Soler; Alexander J Muller; George C Prendergast
Journal:  Cancer Res       Date:  2007-08-15       Impact factor: 12.701

9.  Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma.

Authors:  Hiroshi Urakawa; Yoshihiro Nishida; Hiroatsu Nakashima; Yoshie Shimoyama; Shigeo Nakamura; Naoki Ishiguro
Journal:  Clin Exp Metastasis       Date:  2009-10-06       Impact factor: 5.150

10.  The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.

Authors:  Sung Yong Lee; Hye Kyoung Choi; Kyoung Ju Lee; Jin Yong Jung; Gyu Young Hur; Ki Hwan Jung; Je Hyeong Kim; Chol Shin; Jae Jeong Shim; Kwang Ho In; Kyung Ho Kang; Se Hwa Yoo
Journal:  J Immunother       Date:  2009-01       Impact factor: 4.456

View more
  30 in total

1.  Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.

Authors:  Zachary J Brown; Su Jong Yu; Bernd Heinrich; Chi Ma; Qiong Fu; Milan Sandhu; David Agdashian; Qianfei Zhang; Firouzeh Korangy; Tim F Greten
Journal:  Cancer Immunol Immunother       Date:  2018-06-29       Impact factor: 6.968

2.  IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation.

Authors:  Richard Metz; Courtney Smith; James B DuHadaway; Phillip Chandler; Babak Baban; Lauren M F Merlo; Elizabeth Pigott; Martin P Keough; Sonja Rust; Andrew L Mellor; Laura Mandik-Nayak; Alexander J Muller; George C Prendergast
Journal:  Int Immunol       Date:  2014-01-08       Impact factor: 4.823

3.  IDO is a nodal pathogenic driver of lung cancer and metastasis development.

Authors:  Courtney Smith; Mee Young Chang; Katherine H Parker; Daniel W Beury; James B DuHadaway; Hollie E Flick; Janette Boulden; Erika Sutanto-Ward; Alejandro Peralta Soler; Lisa D Laury-Kleintop; Laura Mandik-Nayak; Richard Metz; Suzanne Ostrand-Rosenberg; George C Prendergast; Alexander J Muller
Journal:  Cancer Discov       Date:  2012-07-19       Impact factor: 39.397

4.  Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival.

Authors:  Debbie M Ferns; Ido P Kema; Marrije R Buist; Hans W Nijman; Gemma G Kenter; Ekaterina S Jordanova
Journal:  Oncoimmunology       Date:  2015-02-25       Impact factor: 8.110

5.  Spontaneous presence of FOXO3-specific T cells in cancer patients.

Authors:  Stine Kiaer Larsen; Shamaila Munir Ahmad; Manja Idorn; Özcan Met; Evelina Martinenaite; Inge Marie Svane; Per Thor Straten; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2014-11-14       Impact factor: 8.110

6.  Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase.

Authors:  Mee Young Chang; Courtney Smith; James B DuHadaway; Jennifer R Pyle; Janette Boulden; Alejandro Peralta Soler; Alexander J Muller; Lisa D Laury-Kleintop; George C Prendergast
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

Review 7.  Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer.

Authors:  George C Prendergast; Courtney Smith; Sunil Thomas; Laura Mandik-Nayak; Lisa Laury-Kleintop; Richard Metz; Alexander J Muller
Journal:  Cancer Immunol Immunother       Date:  2014-04-08       Impact factor: 6.968

Review 8.  The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists.

Authors:  Sunil Thomas; Jacques Izard; Emily Walsh; Kristen Batich; Pakawat Chongsathidkiet; Gerard Clarke; David A Sela; Alexander J Muller; James M Mullin; Korin Albert; John P Gilligan; Katherine DiGuilio; Rima Dilbarova; Walker Alexander; George C Prendergast
Journal:  Cancer Res       Date:  2017-03-14       Impact factor: 12.701

9.  Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.

Authors:  Ayse Basak Engin; Atilla Engin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 10.  Discovery of IDO1 Inhibitors: From Bench to Bedside.

Authors:  George C Prendergast; William P Malachowski; James B DuHadaway; Alexander J Muller
Journal:  Cancer Res       Date:  2017-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.